The ponatinib/gossypol novel combination provides enhanced anticancer activity against murine solid Ehrlich carcinoma via triggering apoptosis and inhibiting proliferation/angiogenesis

Theodor Bilharz Research Institute

Bibliographic Information

Authors: El-Lakkany N.M.; Elkattan H.H.; Elsisi A.E.

Journal: Toxicology and Applied Pharmacology

Publisher: Academic Press Inc.

Publication Date: December 2021

Volume / Issue: Volume 432

Article No.: 115767

ISSN: 0041008X

DOI: 10.1016/j.taap.2021.115767

Scopus: View on Scopus

PubMed: 34699866

Document Type: Article


Authors and Affiliations

El-Lakkany N.M., Department of Pharmacology, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, Giza, 12411, Egypt; Elkattan H.H., Department of Pharmacology, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, Giza, 12411, Egypt; Elsisi A.E., Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt


Abstract

The search for new antitumor agents or combinations that are more effective and, hopefully, provide fewer health hazards is ongoing. Therefore, this study investigated the efficacy of a novel combination of ponatinib, a multi-targeted tyrosine kinase inhibitor, and the natural phytochemical gossypol against murine solid Ehrlich carcinoma. Six groups of ten mice each received vehicle (I), ponatinib in doses of 10 and 15 mg/kg (II, III) respectively, gossypol in a dose of 4 mg/kg (IV), and ponatinib (10 or 15 mg/kg) in combination with gossypol (4 mg/kg; V, VI). All treatments started on the 12th post-Ehrlich ascites carcinoma (EAC) implantation day and were administered intraperitoneally in daily doses for 3 weeks. Treatment of EAC-bearing mice with ponatinib/gossypol combination improved anticancer efficacy over either drug alone, as demonstrated by greater decreases in tumor weight and volume, and ponatinib (10 mg/kg)/gossypol combination was more efficient than ponatinib (15 mg/kg). Mechanistically, the ponatinib/gossypol combination significantly increased apoptotic markers p53, Bax, and caspase-9 while decreasing anti-apoptotic marker Bcl-2. Furthermore, it greatly decreased proliferative and angiogenic markers, FGFR4 and VEGF, respectively. Histopathology revealed a significant decline in neoplastic cells, the majority of which have necrotic changes and numerous apoptotic bodies, as well as a decrease in mitotic figures and tumor giant cells, indicating the capacity to suppress cancer proliferation/persistence. Overall, gossypol could be used as an adjuvant medication for ponatinib in cancer treatment, possibly leading to successful dose reductions and fewer side effects; however, further research is needed before a clinical application could be feasible. © 2021 Elsevier Inc.


Keywords

Angiogenesis; Apoptosis; FGFR4; Gossypol; Ponatinib; Solid Ehrlich tumor; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cell Proliferation; Female; Imidazoles; Mice; Neovascularization, Pathologic; Oxidative Stress; Pyridazines; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction; Tumor Burden; Vascular Endothelial Growth Factor A; caspase 9; fibroblast growth factor receptor 4; gossypol acetic acid; protein Bax; protein bcl 2; protein p53; vasculotropin; angiogenesis inhibitor; antineoplastic agent; apoptosis regulatory protein; Fgfr4 protein, mouse; imidazole derivative; pyridazine derivative; vascular endothelial growth factor A, mouse; vasculotropin A; adult; animal experiment; animal model; animal tissue; antiangiogenic activity; antineoplastic activity; Article; cancer inhibition; controlled study; dose response; drug dose comparison; drug efficacy; drug mechanism; Ehrlich ascites tumor; giant cell; histopathology; mitosis; mouse; nonhuman; tumor volume; tumor weight; animal; drug effect; metabolism; neovascularization (pathology); pathology; tumor cell line


Citation Information

Scopus Citations: 15


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects